We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $4.46B
This Fund
S&P 500
This Quarter Est. Return
+74.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.46B
AUM Growth
+$1.09B
Cap. Flow
-$3.1M
Cap. Flow %
-0.07%
Top 10 Hldgs %
49.45%
Holding
523
New
34
Increased
205
Reduced
238
Closed
35

Top Buys

Rank Stock Value
1
LRCX icon
Lam Research
LRCX
+$149M
2
AMD icon
Advanced Micro Devices
AMD
+$114M
3
ASML icon
ASML
ASML
+$83.3M
4
INTC icon
Intel
INTC
+$69.9M
5
KLAC icon
KLA
KLAC
+$61.9M

Top Sells

Rank Stock Value
1
LITE icon
Lumentum
LITE
+$172M
2
AXTI icon
AXT Inc
AXTI
+$110M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$97.9M
4
GLW icon
Corning
GLW
+$87.2M
5
TSEM icon
Tower Semiconductor
TSEM
+$79.8M

Sector Composition

Rank Sector Weight
1 Technology 66.9%
2 Consumer Discretionary 12.6%
3 Communication Services 5.91%
4 Miscellaneous 3.42%
5 Healthcare 3.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
476
Altimmune
ALT
$665M
$96.5K ﹤0.01%
31,734
+2,662
+9% +$7.95K
IRWD icon
477
Ironwood Pharmaceuticals
IRWD
$704M
$90.8K ﹤0.01%
21,556
-5,674
-21% -$21.9K
OCGN icon
478
Ocugen
OCGN
$461M
$83.9K ﹤0.01%
54,817
+19,255
+54% +$29.3K
SVRA icon
479
Savara
SVRA
$1.1B
$77.2K ﹤0.01%
12,527
-11,225
-47% -$60.2K
PRME icon
480
Prime Medicine
PRME
$671M
$75.6K ﹤0.01%
20,484
-6,615
-24% -$22K
ABUS icon
481
Arbutus Biopharma
ABUS
$1.02B
$69.1K ﹤0.01%
14,406
-1,037
-7% -$4.55K
MYGN icon
482
Myriad Genetics
MYGN
$305M
$67.5K ﹤0.01%
11,819
-2,890
-20% -$13.1K
CABA icon
483
Cabaletta Bio
CABA
$588M
$64.1K ﹤0.01%
+20,601
New +$67.8K
CMPX icon
484
Compass Therapeutics
CMPX
$429M
$58.7K ﹤0.01%
26,808
+2,186
+9% +$6.45K
CATX icon
485
Perspective Therapeutics
CATX
$357M
$53.9K ﹤0.01%
15,820
+4,153
+36% +$15.7K
OVID icon
486
Ovid Therapeutics
OVID
$547M
$51.9K ﹤0.01%
+19,286
New +$49.8K
VSTM icon
487
Verastem
VSTM
$743M
$50.7K ﹤0.01%
13,283
-434
-3% -$2.1K
MDXG icon
488
MiMedx Group
MDXG
$666M
$44.6K ﹤0.01%
11,589
-3,954
-25% -$14.4K
ABVX
489
Abivax
ABVX
$10B
– –
-13,732
Closed -$1.53M
ACLX
490
DELISTED
Arcellx
ACLX
– –
-5,084
Closed -$584K
AKBA icon
491
Akebia Therapeutics
AKBA
$270M
– –
-41,119
Closed -$57.2K
ALB icon
492
Albemarle
ALB
$14.9B
– –
-1,695
Closed -$304K
APLS
493
DELISTED
Apellis Pharmaceuticals
APLS
– –
-22,686
Closed -$913K
AVXL icon
494
Anavex Life Sciences
AVXL
$265M
– –
-18,070
Closed -$55.5K
AZO icon
495
AutoZone
AZO
$48.7B
– –
-62
Closed -$209K
CBOE icon
496
Cboe Global Markets
CBOE
$31.2B
– –
-1,436
Closed -$404K
CHTR icon
497
Charter Communications
CHTR
$18.1B
– –
-4,361
Closed -$941K
CSGP icon
498
CoStar Group
CSGP
$12.5B
– –
-14,915
Closed -$602K
DSX icon
499
Diana Shipping
DSX
$374M
– –
-506,943
Closed -$1.27M
EBS icon
500
Emergent Biosolutions
EBS
$318M
– –
-10,710
Closed -$88.9K
17 18 19
20
21

Similar funds

ACM
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
MAM
Magellan Asset Management Sydney, Australia $4.47B AUM 4.2% 1-Year Est. Return
AP
Americana Partners Houston, Texas $4.44B AUM 29.45% 1-Year Est. Return
BP
BC Partners New York $4.43B AUM 49.12% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
AOI
Auto-Owners Insurance Lansing, Michigan $4.43B AUM 30.05% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

E Fund Management's Q2 2026 Portfolio in Review

As of Q2 2026, E Fund Management held 523 positions worth $4.46B, up 32% from $3.37B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

E Fund Management's Q2 2026 filing shows 34 new, 205 increased, 238 reduced and 35 closed positions. Its largest new stake was Astera Labs: 196,877 shares worth $95.1M. The largest sale was Lumentum, an estimated $172M.

By sector, the portfolio is most concentrated in Technology at 67% of assets, up from 52% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • E Fund Management's largest Q2 2026 buy was Astera Labs: 196,877 shares worth $95.1M.
  • E Fund Management added most to Lam Research in Q2 2026, an estimated $149M increase.
  • E Fund Management's biggest Q2 2026 reduction was Lumentum, cutting an estimated $172M.
  • E Fund Management fully exited SPDR Gold MiniShares Trust in Q2 2026, selling an estimated $13.4M.
  • E Fund Management's ten largest holdings make up 49% of its $4.46B portfolio in Q2 2026.
  • E Fund Management opened 34 new positions and closed 35 in Q2 2026.
  • E Fund Management's portfolio value rose 32% quarter-over-quarter to $4.46B.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.